| Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA MA Coelho, S de Carné Trécesson, S Rana, D Zecchin, C Moore, ... Immunity 47 (6), 1083-1099. e6, 2017 | 549 | 2017 |
| The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer MS Kumar, DC Hancock, M Molina-Arcas, M Steckel, P East, ... Cell 149 (3), 642-655, 2012 | 314 | 2012 |
| Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′, 2′-difluorodeoxycytidine-induced cytotoxicity J García-Manteiga, M Molina-Arcas, FJ Casado, A Mazo, ... Clinical Cancer Research 9 (13), 5000-5008, 2003 | 269 | 2003 |
| Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers CF Houlihan, N Vora, T Byrne, D Lewer, G Kelly, J Heaney, S Gandhi, ... The Lancet 396 (10246), e6-e7, 2020 | 249 | 2020 |
| Nucleoside transporter proteins M Molina-Arcas, FJ Casado, M Pastor-Anglada Current vascular pharmacology 7 (4), 426-434, 2009 | 207 | 2009 |
| Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies M Steckel, M Molina-Arcas, B Weigelt, M Marani, PH Warne, H Kuznetsov, ... Cell research 22 (8), 1227-1245, 2012 | 200 | 2012 |
| Coordinate Direct Input of Both KRAS and IGF1 Receptor to Activation of PI3 kinase in KRAS-Mutant Lung Cancer M Molina-Arcas, DC Hancock, C Sheridan, MS Kumar, J Downward Cancer discovery 3 (5), 548-563, 2013 | 183 | 2013 |
| Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer M Molina-Arcas, C Moore, S Rana, F Van Maldegem, E Mugarza, ... Science translational medicine 11 (510), eaaw7999, 2019 | 181 | 2019 |
| Cell entry and export of nucleoside analogues M Pastor-Anglada, P Cano-Soldado, M Molina-Arcas, MP Lostao, ... Virus research 107 (2), 151-164, 2005 | 171 | 2005 |
| Transport of lamivudine [(-)-β-l-2′, 3′-dideoxy-3′-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation … G Minuesa, C Volk, M Molina-Arcas, V Gorboulev, I Erkizia, P Arndt, ... Journal of pharmacology and experimental therapeutics 329 (1), 252-261, 2009 | 162 | 2009 |
| Estimating the effectiveness of routine asymptomatic PCR testing at different frequencies for the detection of SARS-CoV-2 infections J Hellewell, TW Russell, R Beale, G Kelly, C Houlihan, E Nastouli, ... BMC medicine 19, 1-10, 2021 | 142 | 2021 |
| Nucleoside transporters in chronic lymphocytic leukaemia M Pastor-Anglada, M Molina-Arcas, FJ Casado, B Bellosillo, D Colomer, ... Leukemia 18 (3), 385-393, 2004 | 138 | 2004 |
| Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia M Molina-Arcas, B Bellosillo, FJ Casado, E Montserrat, J Gil, D Colomer, ... Blood, The Journal of the American Society of Hematology 101 (6), 2328-2334, 2003 | 138 | 2003 |
| RAC1P29S induces a mesenchymal phenotypic switch via serum response factor to promote melanoma development and therapy resistance DA Lionarons, DC Hancock, S Rana, P East, C Moore, MM Murillo, ... Cancer cell 36 (1), 68-83. e9, 2019 | 115 | 2019 |
| Antibodies against endogenous retroviruses promote lung cancer immunotherapy KW Ng, J Boumelha, KSS Enfield, J Almagro, H Cha, O Pich, T Karasaki, ... Nature 616 (7957), 563-573, 2023 | 98 | 2023 |
| Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma S Marcé, M Molina-Arcas, N Villamor, FJ Casado, E Campo, ... Haematologica 91 (7), 895-902, 2006 | 97 | 2006 |
| Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells M Molina-Arcas, S Marce, N Villamor, I Huber-Ruano, FJ Casado, ... Leukemia 19 (1), 64-68, 2005 | 84 | 2005 |
| Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells G Minuesa, S Purcet, I Erkizia, M Molina-Arcas, M Bofill, ... Journal of Pharmacology and Experimental Therapeutics 324 (2), 558-567, 2008 | 83 | 2008 |
| RAS signalling through PI3-Kinase controls cell migration via modulation of Reelin expression E Castellano, M Molina-Arcas, AA Krygowska, P East, P Warne, A Nicol, ... Nature communications 7 (1), 11245, 2016 | 70 | 2016 |
| SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers GG Jones, IB Del Río, S Sari, A Sekerim, LC Young, N Hartig, ... Nature communications 10 (1), 2532, 2019 | 67 | 2019 |
